Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Eurofins Scientific

BATS-CHIXE:ERFP
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ERFP
BATS-CHIXE
€8B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Eurofins Scientific SE, through its subsidiaries, provides various analytical testing services worldwide. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
ERFP Share Price and Events
7 Day Returns
-6.5%
BATS-CHIXE:ERFP
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
13.5%
BATS-CHIXE:ERFP
-15.8%
GB Life Sciences
-23%
GB Market
ERFP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eurofins Scientific (ERFP) -6.5% -7.1% -14.4% 13.5% 2.9% 65%
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • ERFP outperformed the Life Sciences industry which returned -15.8% over the past year.
  • ERFP outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
ERFP
Industry
5yr Volatility vs Market

ERFP Value

 Is Eurofins Scientific undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eurofins Scientific to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eurofins Scientific.

BATS-CHIXE:ERFP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.3%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:ERFP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.033 (1 + (1- 26.01%) (43.84%))
1.246
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.25
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.246 * 5.44%)
7.31%

Discounted Cash Flow Calculation for BATS-CHIXE:ERFP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eurofins Scientific is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:ERFP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.31%)
2020 385.50 Analyst x11 359.24
2021 488.36 Analyst x11 424.09
2022 568.63 Analyst x8 460.14
2023 658.00 Analyst x1 496.19
2024 720.83 Est @ 9.55% 506.54
2025 770.16 Est @ 6.84% 504.34
2026 808.28 Est @ 4.95% 493.24
2027 837.57 Est @ 3.62% 476.29
2028 860.15 Est @ 2.7% 455.81
2029 877.75 Est @ 2.05% 433.44
Present value of next 10 years cash flows €4,609.00
BATS-CHIXE:ERFP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €877.75 × (1 + 0.53%) ÷ (7.31% – 0.53%)
€13,013.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €13,013.04 ÷ (1 + 7.31%)10
€6,426.00
BATS-CHIXE:ERFP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €4,609.00 + €6,426.00
€11,035.00
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €11,035.00 / 17.91
€615.97
BATS-CHIXE:ERFP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:ERFP represents 0.93792x of ENXTPA:ERF
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93792x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 615.97 x 0.93792
€577.73
Value per share (EUR) From above. €577.73
Current discount Discount to share price of €423.00
= -1 x (€423.00 - €577.73) / €577.73
26.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Eurofins Scientific is available for.
Intrinsic value
27%
Share price is €423 vs Future cash flow value of €577.73
Current Discount Checks
For Eurofins Scientific to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Eurofins Scientific's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Eurofins Scientific's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eurofins Scientific's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eurofins Scientific's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:ERFP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €8.17
ENXTPA:ERF Share Price ** ENXTPA (2020-03-30) in EUR €451
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eurofins Scientific.

BATS-CHIXE:ERFP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ERF Share Price ÷ EPS (both in EUR)

= 451 ÷ 8.17

55.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurofins Scientific is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • Eurofins Scientific is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Eurofins Scientific's expected growth come at a high price?
Raw Data
BATS-CHIXE:ERFP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 55.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
26.3%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:ERFP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 55.17x ÷ 26.3%

2.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurofins Scientific is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Eurofins Scientific's assets?
Raw Data
BATS-CHIXE:ERFP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €158.55
ENXTPA:ERF Share Price * ENXTPA (2020-03-30) in EUR €451
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:ERFP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ERF Share Price ÷ Book Value per Share (both in EUR)

= 451 ÷ 158.55

2.84x

* Primary Listing of Eurofins Scientific.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurofins Scientific is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Eurofins Scientific's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Eurofins Scientific has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ERFP Future Performance

 How is Eurofins Scientific expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eurofins Scientific expected to grow at an attractive rate?
  • Eurofins Scientific's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Eurofins Scientific's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Eurofins Scientific's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:ERFP Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:ERFP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 26.3%
BATS-CHIXE:ERFP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 5.9%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:ERFP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:ERFP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 6,140 3
2023-12-31 5,817 1,117 529 3
2022-12-31 5,534 988 438 12
2021-12-31 5,269 906 385 14
2020-12-31 4,898 792 289 13
2020-03-31
BATS-CHIXE:ERFP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 4,563 678 146
2019-09-30 4,384 618 144
2019-06-30 4,206 558 143
2019-03-31 3,993 551 159
2018-12-31 3,781 544 175
2018-09-30 3,549 521 182
2018-06-30 3,318 498 190
2018-03-31 3,145 451 185
2017-12-31 2,971 405 179
2017-09-30 2,848 387 166
2017-06-30 2,725 369 152
2017-03-31 2,631 370 145

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eurofins Scientific's earnings are expected to grow significantly at over 20% yearly.
  • Eurofins Scientific's revenue is expected to grow by 5.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:ERFP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Eurofins Scientific Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:ERFP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 25.39 29.27 18.24 7.00
2021-12-31 22.25 25.33 15.97 9.00
2020-12-31 17.31 21.22 13.07 9.00
2020-03-31
BATS-CHIXE:ERFP Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 8.17
2019-09-30 8.12
2019-06-30 8.06
2019-03-31 8.98
2018-12-31 9.90
2018-09-30 10.38
2018-06-30 10.86
2018-03-31 10.68
2017-12-31 10.49
2017-09-30 9.78
2017-06-30 9.06
2017-03-31 8.86

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Eurofins Scientific is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Eurofins Scientific's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eurofins Scientific has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ERFP Past Performance

  How has Eurofins Scientific performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eurofins Scientific's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eurofins Scientific's year on year earnings growth rate has been positive over the past 5 years.
  • Eurofins Scientific's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Eurofins Scientific's 1-year earnings growth is negative, it can't be compared to the Europe Life Sciences industry average.
Earnings and Revenue History
Eurofins Scientific's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eurofins Scientific Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:ERFP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 4,562.80 145.50 117.20
2019-09-30 4,384.13 144.27 111.39
2019-06-30 4,205.51 143.07 105.54
2019-03-31 3,993.33 159.19 97.70
2018-12-31 3,781.10 175.30 89.90
2018-09-30 3,549.45 182.45 82.39
2018-06-30 3,317.80 189.60 74.88
2018-03-31 3,144.61 184.52 61.62
2017-12-31 2,971.42 179.44 48.36
2017-09-30 2,848.28 165.66 41.71
2017-06-30 2,725.14 151.89 35.06
2017-03-31 2,630.88 145.13 36.71
2016-12-31 2,536.61 138.37 38.36
2016-09-30 2,426.59 103.84 35.29
2016-06-30 2,316.56 69.31 32.22
2016-03-31 2,133.32 62.83 31.32
2015-12-31 1,950.07 56.36 30.42
2015-09-30 1,779.35 71.01 27.16
2015-06-30 1,608.63 85.67 23.90
2015-03-31 1,509.43 81.82 19.56
2014-12-31 1,410.23 77.98 15.22
2014-09-30 1,354.52 65.59 16.97
2014-06-30 1,298.81 53.20 18.71
2014-03-31 1,262.19 53.16 15.14
2013-12-31 1,225.57 53.13 11.57
2013-09-30 1,179.71 61.24 8.05
2013-06-30 1,133.85 69.35 4.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Eurofins Scientific has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Eurofins Scientific used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Eurofins Scientific's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Eurofins Scientific's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eurofins Scientific has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ERFP Health

 How is Eurofins Scientific's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eurofins Scientific's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eurofins Scientific is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eurofins Scientific's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Eurofins Scientific's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eurofins Scientific Company Filings, last reported 3 months ago.

BATS-CHIXE:ERFP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2,898.10 2,973.50 297.30
2019-09-30 2,898.10 2,973.50 297.30
2019-06-30 2,739.53 3,001.17 304.58
2019-03-31 2,739.53 3,001.17 304.58
2018-12-31 2,722.20 3,109.00 507.90
2018-09-30 2,722.20 3,109.00 507.90
2018-06-30 2,552.81 2,197.88 558.99
2018-03-31 2,552.81 2,197.88 558.99
2017-12-31 2,481.97 2,199.34 820.36
2017-09-30 2,481.97 2,199.34 820.36
2017-06-30 1,699.92 1,334.27 575.16
2017-03-31 1,699.92 1,334.27 575.16
2016-12-31 1,756.71 1,371.34 826.10
2016-09-30 1,756.71 1,371.34 826.10
2016-06-30 1,315.61 1,631.95 811.59
2016-03-31 1,315.61 1,631.95 811.59
2015-12-31 1,080.31 1,700.09 793.76
2015-09-30 1,080.31 1,700.09 793.76
2015-06-30 1,010.31 1,160.26 756.98
2015-03-31 1,010.31 1,160.26 756.98
2014-12-31 664.24 712.34 216.62
2014-09-30 664.24 712.34 216.62
2014-06-30 404.32 878.72 378.37
2014-03-31 404.32 878.72 378.37
2013-12-31 394.74 683.90 297.26
2013-09-30 394.74 683.90 297.26
2013-06-30 360.34 515.10 117.48
  • Eurofins Scientific's level of debt (102.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (107.3% vs 102.6% today).
  • Debt is well covered by operating cash flow (22.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.7x coverage).
X
Financial health checks
We assess Eurofins Scientific's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eurofins Scientific has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ERFP Dividends

 What is Eurofins Scientific's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.76%
Current annual income from Eurofins Scientific dividends. Estimated to be 1.13% next year.
If you bought €2,000 of Eurofins Scientific shares you are expected to receive €15 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Eurofins Scientific's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.69%).
  • Eurofins Scientific's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.48%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:ERFP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:ERFP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31 6.11 1.00
2022-12-31 5.99 11.00
2021-12-31 5.20 14.00
2020-12-31 4.21 14.00
2020-03-31
BATS-CHIXE:ERFP Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-03-04 3.450 0.780
2019-03-05 2.880 0.686
2018-03-06 2.400 0.581
2016-02-29 1.450 0.370
2015-03-02 1.320 0.458
2014-06-20 1.200 0.570
2013-03-15 1.000 0.548
2012-04-03 0.800 0.723
2011-03-22 0.200 0.321
2010-02-16 0.100 0.256

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eurofins Scientific is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Eurofins Scientific is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Eurofins Scientific's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Eurofins Scientific's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • No need to calculate the sustainability of Eurofins Scientific's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Eurofins Scientific's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eurofins Scientific afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eurofins Scientific has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ERFP Management

 What is the CEO of Eurofins Scientific's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gilles Martin
COMPENSATION €1,189,214
AGE 56
CEO Bio

Dr. Gilles G. Martin, Ph.D., serves as the Chief Executive Officer at Eurofins Scientific, Inc. Dr. Martin serves as Chief Executive Officer of Eurofins Nihon Kankyo K.K. and Eurofins Scientific Group. He serves as Chairman of the Board and Chief Executive Officer of Eurofins Scientific SE and served as its Chairman of Management Board and Member of Management Board. He founded the original Eurofins Scientific Nantes food authenticity laboratory in 1988. Dr. Martin is an international expert witness in his field and belongs to various standardization bodies in Europe and North America. He has extensive international business and management experience in the life-science and analytical tools industries, including specialized expertise in the envienvironmental testing, food safety analysis and pharmaceutical clinical research markets. He served as President of the French Association of private analytical laboratories APROLAB, of the North American Technical Committee for Juice and Juice Products (TCJJP) and of French public bodies supporting technological innovation. He serves as the Chairman of Eurofins Nihon Kankyo K.K. Dr. Martin served as the Chairman of Supervisory Board and Member of Supervisory Board at Eurofins Scientific SA. He has been a Director of Eurofins Scientific SE since 1988. He has been a Director at Bruker Corporation since January 13, 2014. He served as a Member of the Supervisory Board at GeneScan Europe AG until October 21, 2008. He graduated from Ecole Centrale Paris. He also has a Master of Science from Syracuse University (New York) and a PhD in Statistics and Applied Mathematics from Ecole Centrale de Paris.

CEO Compensation
  • Gilles's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Gilles's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Gilles Martin

TITLE
Chairman of the Board & CEO
COMPENSATION
€1M
AGE
56

Valerie Hanote

TITLE
Executive Director
COMPENSATION
€294K
AGE
53

Yves-Loïc Martin

TITLE
Executive Director
COMPENSATION
€354K
AGE
53

Laurent Lebras

TITLE
Group Administration & Finance Director

Dirk Bontridder

TITLE
Group Executive VP of President Pharmaceutical Services & Member of Management Board
AGE
46
TENURE
11.3 yrs

Markus Brandmeier

TITLE
Group Executive VP of Food Testing & Member of The Executive Board
AGE
55
Board of Directors Tenure

Average tenure and age of the Eurofins Scientific board of directors in years:

8.2
Average Tenure
55.5
Average Age
  • The tenure for the Eurofins Scientific board of directors is about average.
Board of Directors

Gilles Martin

TITLE
Chairman of the Board & CEO
COMPENSATION
€1M
AGE
56

Valerie Hanote

TITLE
Executive Director
COMPENSATION
€294K
AGE
53
TENURE
30.2 yrs

Yves-Loïc Martin

TITLE
Executive Director
COMPENSATION
€354K
AGE
53
TENURE
28.2 yrs

Stuart Anderson

TITLE
Independent Non-Executive Director
COMPENSATION
€78K
AGE
77
TENURE
8.2 yrs

Fereshteh Pouchantchi

TITLE
Independent Non-Executive Director
COMPENSATION
€78K
AGE
65
TENURE
5.8 yrs

Patrizia Luchetta

TITLE
Independent Non-Executive Director
COMPENSATION
€78K
AGE
55
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Eurofins Scientific's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eurofins Scientific has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ERFP News

Simply Wall St News

ERFP Company Info

Description

Eurofins Scientific SE, through its subsidiaries, provides various analytical testing services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as for clinical diagnostic. It provides agro science, agro testing, biopharma, contract development and manufacturing organization, clinical diagnostics, consumer product testing, cosmetics testing, digital testing, electrical and electronics, environment testing, food and feed testing, forensic, genomic, industrial, materials and engineering, medical device, and REACH services. The company serves clients from a range of industries, including the pharmaceutical, food, environmental, and clinical diagnostics sectors. It operates approximately 800 laboratories in 47 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

Details
Name: Eurofins Scientific SE
ERFP
Exchange: BATS-CHIXE
Founded: 1987
€8,079,604,115
17,914,865
Website: http://www.eurofins.com
Address: Eurofins Scientific SE
Val Fleuri 23,
Luxembourg City,
1526,
Luxembourg
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ERF Ordinary Shares Euronext Paris FR EUR 07. Nov 1997
OTCPK ERFS.F Ordinary Shares Pink Sheets LLC US USD 07. Nov 1997
DB ESF Ordinary Shares Deutsche Boerse AG DE EUR 07. Nov 1997
LSE 0MV5 Ordinary Shares London Stock Exchange GB EUR 07. Nov 1997
SWX ERF Ordinary Shares SIX Swiss Exchange CH CHF 07. Nov 1997
ETLX ESF Ordinary Shares Eurotlx IT EUR 07. Nov 1997
BATS-CHIXE ERFP Ordinary Shares BATS 'Chi-X Europe' GB EUR 07. Nov 1997
ENXTPA ERFNV EUR0.1 (RFD 01/01/2020) Euronext Paris FR EUR 02. Jan 2020
OTCPK ERRF.Y UNSPONSORE ADR Pink Sheets LLC US USD 08. May 2017
Number of employees
Current staff
Staff numbers
47,427
Eurofins Scientific employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 19:50
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/04
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.